Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 5;33(1):79–91. doi: 10.1007/s40259-018-00331-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

OpenAccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 2 — Efficacy of CT-P10 and combined rituximab over 48 weeks (efficacy population)^a: a mean change from baseline in DAS28-ESR; b DAS28-CRP; c proportion of patients achieving ACR20, ACR50, and ACR70 criteria; and d mean hybrid ACR score. ^aData after week 24 are from the efficacy population–2nd treatment course subset. ACR American College of Rheumatology, CRP C-reactive protein, DAS28 Disease Activity Score 28-Joint Count, ESR erythrocyte sedimentation rate, RTX rituximab, SD standard deviation, SE standard error